The pharmaceutical company Binnopharm Group has been recognized at the prestigious Eurasian Pharma Awards. The competition is being held for the sixth year in a row and brings together leading companies and pharmaceutical industry specialists from Central Asia, the Caucasus, and Eastern Europe.
The winners were announced at the Eurasian Pharmaceutical Summit held in Tashkent, on October 7. Following the results of the competition, Binnopharm Group won in the Regulatory strategy of the year nomination. This award is given to a company that has successfully executed a strategy for expanding its market presence within the EAEU and internationally.
Since the beginning of 2025, Binnopharm Group has received about 40 registration certificates for its products in the EAEU countries and neighboring countries, including Russia, Azerbaijan, Belarus, Moldova, Mongolia, Turkmenistan, Tajikistan, and Uzbekistan. The company has completed registration procedures—complying with both EAEU requirements and national standards—for its key therapeutic areas. These include antibacterial drugs, as well as medications for cardiovascular, hematological, and gastrointestinal disorders.
“We have established a well-defined system for drug preparation and registration, enabling rapid market entry and ensuring patients have access to necessary medications. Thanks to our well-established collaboration processes with foreign regulatory authorities, we are executing our strategy to scale the product portfolio in international markets,” said Gulnara Setdekova, Director of Development and Registration at Binnopharm Group.
According to her, starting in 2023, the company has been expanding its international presence in the markets of Southeast Asian countries. Registration dossiers for a number of drugs, prepared in accordance with both local and ASEAN requirements, are already complete. The necessary regulatory procedures have been initiated to submit applications for registration and to obtain GMP PIC/S certification.
The Eurasian Pharma Awards celebrate genuine breakthroughs, inspiring projects, and the people driving the transformation of the pharmaceutical industry in the region. In 2025, applications were accepted across 15 categories. Over the years, various Russian and foreign companies have won the award: R-Pharm (Russia), AstraZeneca, Nika Pharm (Uzbekistan), Gedeon Richter (Kazakhstan), and others.